Our findings open therefore a vast field of clinical investigation aimed at evaluating the action of NK1R antagonists on aldosterone production and organ protection in various cardiovascular, renal and metabolic diseases, potentially enlarging their clinical use from antiemesis to cardiorenal prevention. The gene discussed is TACR1; the disease is metabolic disease.